Sugi Predict

Sugi Predict / Compounds / SCHEMBL219677

SCHEMBL219677

SCHEMBL219677

O=Cc1ccc(O)c(Cl)c1Cl

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ERN1 O75460 8/20 0.54
▸ CYP3A4 P08684 1/20 0.48
▸ MAPK1 P28482 1/20 0.48
▸ TRIM24 O15164 2/20 0.44
▸ TRIM33 Q9UPN9 2/20 0.44
▸ TDP1 Q9NUW8 2/20 0.41
▸ RAB9A P51151 3/20 0.40
▸ KDM4E B2RXH2 2/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ NPC1 O15118 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ NPSR1 Q6W5P4 2/20 0.40
▸ L3MBTL1 Q9Y468 2/20 0.40
▸ HSP90AA1 P07900 1/20 0.40
▸ IDO1 P14902 1/20 0.40
▸ TYR P14679 2/20 0.39
▸ CDK1 P06493 1/20 0.38
▸ PTGS2 P35354 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31300223 1.00 ERN1 (0.54) ERN1CYP3A4MAPK1TRIM24TRIM33
SCHEMBL10413565 0.84 TDP1 (0.52) ERN1CYP3A4TRIM24TRIM33TDP1
SCHEMBL1982095 0.84 ERN1 (0.52) ERN1TRIM24TRIM33TDP1RAB9A
SCHEMBL29915579 0.84 ERN1 (0.52) ERN1TRIM24TRIM33TDP1RAB9A
SCHEMBL14331344 0.84 ERN1 (0.52) ERN1CYP3A4MAPK1TRIM24TRIM33
Hydrochloric Acid SCHEMBL29595412 0.82 ERN1 (0.50) ERN1TRIM24TRIM33TDP1RAB9A
SCHEMBL29954266 0.80 ERN1 (0.48) ERN1CYP3A4MAPK1TRIM24TRIM33
SCHEMBL7045902 0.80 ERN1 (0.48) ERN1TRIM24TRIM33TDP1RAB9A
SCHEMBL29955049 0.80 ERN1 (0.48) ERN1TRIM24TRIM33TDP1RAB9A
SCHEMBL18729174 0.80 ERN1 (0.48) ERN1CYP3A4MAPK1TRIM24TRIM33

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113372268-A 4-oxo-6-methoxy-3- (2, 3-dichlorophenyl) methyl-1 (4H) quinolineacetic acid metabolites 宁夏康亚药业股份有限公司 2021-09-10 — — CN claimed
EP-4689155-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS Astrazeneca AB (SE) 2026-02-11 — — EP disclosed
EP-4630410-A1 POLQ INHIBITORS Astrazeneca AB (SE) 2025-10-15 — — EP disclosed
EP-4619097-A1 AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF Samsara Therapeutics Inc. (US) 2025-09-24 — — EP disclosed
US-12414954-B2 POLQ inhibitors ASTRAZENECA AB (SE) 2025-09-16 — — US disclosed
US-20250195530-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2025-06-19 — — US disclosed
US-20240366615-A1 POLQ INHIBITORS ASTRAZENECA UK LIMITED (GB) 2024-11-07 — — US disclosed
WO-2024201368-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS ASTRAZENECA AB (SE) 2024-10-03 — — WO disclosed
CN-115850043-B Synthesis method of p-hydroxybenzaldehyde 浙江新化化工股份有限公司 2024-08-06 — — CN disclosed
WO-2024121753-A1 POLQ INHIBITORS ASTRAZENECA AB (SE) 2024-06-13 — — WO disclosed
CN-87106895-A Phenoxyacetic acid derivatives and process for producing the same — 1988-04-20 — — CN disclosed
EP-0240256-A2 Compounds useful in treating sickle cell anemia MERCK & CO. INC. (US) 1987-10-07 — — EP disclosed
EP-0027948-B1 TETRAHYDRO-FLUORENE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF MERCK & CO. INC. (US) 1984-03-21 — — EP disclosed
US-4389416-A DIURETICS ABBOTT LABORATORIES (US) 1983-06-21 — — US disclosed
US-4356314-A [5,6,9A-Substituted-3-oxo-1,2,9,9a-tetrahydro-3H-fluoren-7-yl)oxy]alkanoic and cycloalkanoic acids, their analogs, esters, salts, and derivatives MERCK & CO., INC. (US) 1982-10-26 — — US disclosed
US-4356313-A [(5,6,9a-substituted-3-oxo-1,2,9,9a-tetrahydro-3H-fluoren-7-yl)oxy]alkanoic and cycloalkanoic acid esters and their analogs, the parent acids and their salts MERCK & CO., INC. (US) 1982-10-26 — — US disclosed
US-4337354-A BRAIN AND SPINAL CHORD DAMAGE MERCK & CO., INC. (US) 1982-06-29 — — US disclosed
US-4317922-A [(5,6,9a-Substituted-3-oxo-1,2,9,9a-tetrahydro-3H-fluoren-7-yl)oxy]alkanoic and cycloalkanoic acids and their analogs, esters, salts and derivatives MERCK & CO., INC. (US) 1982-03-02 — — US disclosed
US-4316043-A ANTIEDEMIC AGENTS MERCK & CO., INC. (US) 1982-02-16 — — US disclosed
US-4255585-A HYPOTENSIVE, DIURETIC CENTRE EUROPEAN DE RECHERCHES PHARMACOLOGIQUE (FR) 1981-03-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240366615-A1 POLQ INHIBITORS POLQ, POLG, POLB ERN1 1512/4885CYP3A4 2422/4885MAPK1 1866/4885
US-12414954-B2 POLQ inhibitors POLQ, POLG, POLB ERN1 1512/4885CYP3A4 2422/4885MAPK1 1866/4885
US-20250195530-A1 POLQ INHIBITORS POLQ, POLG, POLB ERN1 1512/4885CYP3A4 2422/4885MAPK1 1866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.